LUPIN LTD.
NSE : LUPINBSE : 500257ISIN
CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse
: Lupin
BSE1610.55-69.2 (-4.12 % )
PREV CLOSE (Rs.) 1679.75
OPEN PRICE (Rs.) 1686.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 170189
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE1610.60 -69.05 (-4.11 % )
PREV CLOSE(Rs.) 1679.65
OPEN PRICE (Rs.) 1684.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1610.60 (981 )
VOLUME 5143705
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 07-May-2024 | Lupin reports 52% rise in Q4 consolidated net profit | <p style="text-align: justify;">Lupin has reported results for fourth quarter (Q4) and year ended March 31, 2024.</p><p style="text-align: justify;">The company has reported over 3-fold jump in its net profit at Rs 384.08 crore for the quarter under review as compared to Rs 119.01 crore for the same quarter in the previous year. Total income of the company increased by 18.52% at Rs 3,427.22 crore for Q4FY24 as compared Rs 2,891.57 crore for the corresponding quarter previous year.</p><p style="text-align: justify;">On consolidated basis, the company has reported 51.91% rise in its net profit at Rs 368.22 crore for fourth quarter ended March 31, 2024 as compared to Rs 242.39 crore for the same quarter in the previous year. Total income of the company increased by 11.70% at Rs 4,990.04 crore for Q4FY24 as compared Rs 4,467.35 crore for the corresponding quarter previous year. <span style="white-space:pre"> </span></p><p style="text-align: justify;">For the year ended March 31, 2024, the company has reported over 5-fold jump in net profit at Rs 2,326.09 crore as compared to Rs 425.21 crore for the previous year. Total income of the company increased by 30.16% at Rs 14,773.23 crore for year under review as compared to Rs 11,350.09 crore for year ended March 31, 2023.</p><p style="text-align: justify;">For the year ended March 31, 2024, on the consolidated basis, the company has reported over 4-fold jump in its net profit at Rs 1,935.57 crore as compared to Rs 447.69 crore for the previous year. Total income of the company increased by 20.44% at Rs 20,130.99 crore for year under review as compared to Rs 16,715.02 crore for year ended March 31, 2023.<span style="white-space:pre"> </span></p> |
| 07-May-2024 | Lupin falls despite reporting 52% rise in Q4 consolidated net profit | <p style="text-align: justify;">Lupin is currently trading at Rs. 1605.95, down by 73.80 points or 4.39% from its previous closing of Rs. 1679.75 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1686.70 and has touched a high and low of Rs. 1686.70 and Rs. 1561.00 respectively. So far 149632 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 704.05 on 08-May-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1687.30 and Rs. 1561.00 respectively. The current market cap of the company is Rs. 72038.14 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 46.05% and 6.93% respectively.</p><p style="text-align: justify;">Lupin has reported over 3-fold jump in its net profit at Rs 384.08 crore for the fourth quarter (Q4) ended March 31, 2024 as compared to Rs 119.01 crore for the same quarter in the previous year. Total income of the company increased by 18.52% at Rs 3,427.22 crore for Q4FY24 as compared Rs 2,891.57 crore for the corresponding quarter previous year.</p><p style="text-align: justify;">On consolidated basis, the company has reported 51.91% rise in its net profit at Rs 368.22 crore for fourth quarter ended March 31, 2024 as compared to Rs 242.39 crore for the same quarter in the previous year. Total income of the company increased by 11.70% at Rs 4,990.04 crore for Q4FY24 as compared Rs 4,467.35 crore for the corresponding quarter previous year. <span style="white-space:pre"> </span></p><p style="text-align: justify;">For the year ended March 31, 2024, the company has reported over 5-fold jump in net profit at Rs 2,326.09 crore as compared to Rs 425.21 crore for the previous year. Total income of the company increased by 30.16% at Rs 14,773.23 crore for year under review as compared to Rs 11,350.09 crore for year ended March 31, 2023.</p><p style="text-align: justify;">For the year ended March 31, 2024, on the consolidated basis, the company has reported over 4-fold jump in its net profit at Rs 1,935.57 crore as compared to Rs 447.69 crore for the previous year. Total income of the company increased by 20.44% at Rs 20,130.99 crore for year under review as compared to Rs 16,715.02 crore for year ended March 31, 2023.<span style="white-space:pre"> </span></p><div style="text-align: justify;"><br></div> |
| 07-May-2024 | Lupin informs about investor presentation | <div>Pursuant to Regulation 30(2) read with Schedule III Part A Para A (15)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it enclosed a copy of the Investor Presentation-Q4 FY24.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 07-May-2024 | VA Tech Wabag, Lupin and Mastek to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">VA Tech Wabag </span>has secured a repeat order from Office National De L'assainissement (ONAS). The consortium order entails Design, Build, Operate (DBO), towards a 36 MLD Wastewater Treatment Plant (WTP) valued at 114.22 Million Tunisian Dinars (approx. Euro 34 Million), located at Sousse Hamdoun II, Tunisia. The scope of WABAG under this order will be Engineering & Procurement (‘EP') and Operation & Maintenance (O&M), which is worth about half of the consortium order value. This includes Design, Engineering, Supply, Installation and Commissioning of the plant followed by a One Year O&M phase.</p><p style="text-align: justify;"><span style="font-weight: bold;">Lupin </span>has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), to market a generic equivalent to the reference listed drug (RLD) Travatan Z Ophthalmic Solution, 0.004%, of Sandoz Inc. The product will be manufactured at Lupin's Pithampur facility in India. Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Travoprost Ophthalmic Solution USP, 0.004% (RLD Travatan Z), had estimated annual sales of $77 million in the U.S. (IQVIA MAT March 2024). </p><p style="text-align: justify;"><span style="font-weight: bold;">Mastek </span>has unveiled its iConniX portfolio to enable Gen AI-led innovation across industries. iConniX currently offers over 120 AI assets, 4 AI platforms, and solution blueprints tailored to meet industry specific business use cases. Building on top of personalized automation, intelligent decision-making, and tailored industry solutions, Mastek sets the stage for 'AI as an Experience', enabling businesses to leverage the full potential of Cloud, Data, Analytics, and Customer Experience (CX). It redefines the way companies engage with technology, ML and large language models making AI an integral part of their operations. iConniX will drive productivity, innovation, and long-term business outcomes for organizations.</p><p style="text-align: justify;"><span style="font-weight: bold;">Wipro </span>has collaborated with Microsoft to launch a suite of cognitive assistants for financial services powered by generative artificial intelligence (GenAI): Wipro GenAI Investor Intelligence, Wipro GenAI Investor Onboarding, and Wipro GenAI Loan Origination. Harnessing the power of GenAI, the Wipro cognitive assistants will provide financial professionals with deep market intelligence and relevant and timely information on investment products and investor behavior. The solutions will also accelerate the investor onboarding and loan origination process by significantly reducing the time it takes to validate documents and providing meaningful and contextual responses to investor queries throughout the process.</p><p style="text-align: justify;"><span style="font-weight: bold;">Entero Healthcare Solutions</span>' board has approved inter-alia, to execute the definitive agreements to acquire 80% paidup equity share capital of Avenir Lifecare Pharma (ALPPL) at their meeting held on May 6, 2024. The business of ALPPL is in line of the business of the Company i.e. wholesale distribution of pharmaceutical and other allied products and the acquisition of ALPPL by the company shall enable the Company to expand its business in the State of Telangana and thereby enabling the company to generate additional business and revenue on consolidated basis.</p><p style="text-align: justify;"><span style="font-weight: bold;">Welspun Corp's</span> associate company -- East Pipes Integrated Company for Industry (EPIC) has inked contract with Maramer Contracting Company with value exceeding SAR 60 million (around Rs 133 crore) for manufacturing, coating and supply of steel pipes. The duration of the contract is six months. </p><p style="text-align: justify;"><span style="font-weight: bold;">Indian Overseas Bank</span> (IOB) has planned to sell 92 non-performing loans with an aggregate outstanding of Rs 13,471.68 crore through an e-auction on May 28. The public sector lender invited expressions of interest (EoI) from asset reconstruction Companies (ARCs) and other eligible transferees by May 13 to participate in the auction process.</p> |
| 06-May-2024 | Lupin gets USFDA's approval for Travoprost Ophthalmic Solution | <p style="text-align: justify;">Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), to market a generic equivalent to the reference listed drug (RLD) Travatan Z Ophthalmic Solution, 0.004%, of Sandoz Inc. </p><p style="text-align: justify;">The product will be manufactured at Lupin's Pithampur facility in India. Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Travoprost Ophthalmic Solution USP, 0.004% (RLD Travatan Z), had estimated annual sales of $77 million in the U.S. (IQVIA MAT March 2024).</p><p style="text-align: justify;">Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.</p><div style="text-align: justify;"><br></div> |
| 24-Apr-2024 | Lupin gets EIR for Aurangabad manufacturing facility | <p style="text-align: justify;">Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). </p><p style="text-align: justify;">Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.</p> |
| 24-Apr-2024 | Lupin rises on the BSE | <p style="text-align: justify;">Lupin is currently trading at Rs. 1595.15, up by 14.60 points or 0.92% from its previous closing of Rs. 1580.55 on the BSE. </p><p style="text-align: justify;">The scrip opened at Rs. 1595.00 and has touched a high and low of Rs. 1602.50 and Rs. 1588.15 respectively. So far 7418 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 680.35 on 27-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1634.00 and Rs. 1541.05 respectively. The current market cap of the company is Rs. 72646.57 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 46.05% and 6.93% respectively.</p><p style="text-align: justify;">Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). </p><p style="text-align: justify;">Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.</p><div style="text-align: justify;"><br></div> |
| 22-Apr-2024 | Lupin launches Mirabegron Extended-Release tablets | <p style="text-align: justify;">Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).</p><p style="text-align: justify;">Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).</p><p style="text-align: justify;">Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.</p> |
| 22-Apr-2024 | Lupin informs about board meeting | <p style="text-align: justify;">Pursuant to Regulation 29(1)(a) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Lupin has informed that a meeting of the Board of Directors of the Company will be held on Monday, May 6, 2024, to consider and take on record audited financial results of the Company for the quarter and year-ended March 31, 2024 and recommend dividend, if any.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 22-Apr-2024 | Lupin jumps on launching Mirabegron Extended-Release tablets | <p style="text-align: justify;">Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% from its previous closing of Rs. 1547.05 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 1599.50 and has touched a high and low of Rs. 1603.00 and Rs. 1570.35 respectively. So far 14575 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1703.80 on 11-Mar-2024 and a 52 week low of Rs. 678.90 on 20-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 1640.00 and Rs. 1541.05 respectively. The current market cap of the company is Rs. 72851.65 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 46.05% and 6.93% respectively.</p><p style="text-align: justify;">Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).<br>Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).</p><p style="text-align: justify;">Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.</p><div style="text-align: justify;"><br></div> |
